MGH does it again!

MGH ovarian cancer researchers are hoping to start a clinical trial later this year using losartan, a well known anti-hypertensive, to examine how it can enhance the anti-tumor effects of chemotherapy.

Researchers studying pancreatic cancer, have found that losartan reduces the extracellular matrix around tumor cells. This is significant because the matrix increases the density around tumor cells preventing drugs from penetrating the tumor.

To find out more about this research, follow this link to MGH